Off-Label Drug Repurposing Research for Autoimmune Diseases

Research into off-label drug repurposing research approaches for Autoimmune Diseases. AI-powered analysis of mechanisms, evidence, and clinical status.

About Off-Label Drug Repurposing Research

AI-powered analysis of FDA-approved drugs being repurposed for novel indications — metformin, low-dose naltrexone, rapamycin, statins, and more. Leveraging existing safety profiles for new therapeutic hypotheses.

About Autoimmune Diseases

New autoimmune treatments in 2026: JAK inhibitors, precision immunotherapy, microbiome approaches. AI-analyzed across MS, lupus, RA, and Crohn's.

Standard of Care: Immunosuppressants (methotrexate, azathioprine), biologics (TNF inhibitors, IL-6 blockers, B-cell depleters), JAK inhibitors — primarily symptom control and flare prevention.